---
title: "Chengdu Easton Biopharmaceuticals Co.,Ltd (688513.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688513.SH.md"
symbol: "688513.SH"
name: "Chengdu Easton Biopharmaceuticals Co.,Ltd"
industry: "Pharmaceuticals"
datetime: "2026-05-19T23:13:28.812Z"
locales:
  - [en](https://longbridge.com/en/quote/688513.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688513.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688513.SH.md)
---

# Chengdu Easton Biopharmaceuticals Co.,Ltd (688513.SH)

## Company Overview

Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; Apualutamide, Bosutinib, Dacomitinib, Ibrutinib, Nilotinib HCL, Nintedanib, Relugolix, and Ruxolitinib Phosphate for oncological applications; Bricaracetam and Lacosamide for neurological and psychiatric applications; and Empagliflozin for anti-diabetic applications. The company was founded in 2009 and is based in Chengdu, China.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.eastonpharma.cn](https://www.eastonpharma.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:08.000Z

**Overall: B (0.39)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 28 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.87% |  |
| Net Profit YoY | 22.56% |  |
| P/B Ratio | 3.26 |  |
| Dividend Ratio | 0.77% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 9722929842.90 |  |
| Revenue | 1350721745.86 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 9.54% | B |
| Profit Margin | 20.29% | A |
| Gross Margin | 77.44% | A |
| Revenue YoY | 0.87% | C |
| Net Profit YoY | 22.56% | B |
| Total Assets YoY | 9.15% | B |
| Net Assets YoY | 11.69% | B |
| Cash Flow Margin | 113.58% | C |
| OCF YoY | 0.87% | C |
| Turnover | 0.37 | C |
| Gearing Ratio | 18.31% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Chengdu Easton Biopharmaceuticals Co.,Ltd",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.87%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "22.56%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.26",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.77%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "9722929842.90",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1350721745.86",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "9.54%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "20.29%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "77.44%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "0.87%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "22.56%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "9.15%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "11.69%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "113.58%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "0.87%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.37",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "18.31%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 36.27 | 83/215 | 47.09 | 42.41 | 38.36 |
| PB | 3.33 | 150/215 | 3.97 | 3.61 | 3.26 |
| PS (TTM) | 7.36 | 160/215 | 8.40 | 7.75 | 6.89 |
| Dividend Yield | 0.75% | 112/215 | 0.81% | 0.73% | 0.66% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-06T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 56.35 |
| Highest Target | 43.00 |
| Lowest Target | 43.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688513.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688513.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688513.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**